Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2005

View Archived Issues

Xcytrin with radiosurgery studied in phase II trial for brain metastases

Multi-party collaboration to develop treatments for spinal injury, neurotrauma

NexMed licenses NM-100060 for onychomycosis to Novartis

NicOx and Ferrer expand agreement in dermatology

Preliminary phase I data on VX-001 immunotherapy in cancer patients

Antidiabetic potential of RWJ-348260 evident in preclinical models

(-)-Oleocanthal, a compound in extra-virgin olive oil with ibuprofen-like activity

Preclinical profile and efficacy of CK-1827452 in a model of heart failure

Pharmacokinetics of oral insulin analogue IN-105 resemble those of insulin

KOS-2187: Novel motilide chosen as a clinical candidate

Novel NS5B polymerase inhibitor with in vitro efficacy and in vivo bioavailability

New efforts in avian flu vaccine development

Ziopharm and Easyweb complete merger

Hana Biosciences: pipeline progress

EntreMed enters CRADA with NCI to study HIF-1alpha inhibition in cancer

Cholesterol absorption inhibitor MD-0727 enters phase I testing

Prostaglandin F2alpha antagonist THG-113.31 delays preterm birth in sheep

Interim results for phase II study of Campath in MS

Affiris reports positive preclinical findings for Alzheimer's vaccine

rhGAD65 DNA vaccine prevents insulitis, beta cell apoptosis and diabetes onset in NOD mice

PSN-9301 in combination with metformin improves glucose tolerance in two rat models of diabetes

Remicade now approved in U.S. for ulcerative colitis

New data on the efficacy and safety of indacaterol in asthma and COPD

Recent patents describe new analgesic agents

Novel anti-HIV agents reported by Kumamoto

Agents for thrombotic disorders in early development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...